Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Testing effectiveness (Phase 2)Study completedNCT01362296
What this trial is testing

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 134
Testing effectiveness (Phase 2)WithdrawnNCT05180422
What this trial is testing

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Who this might be right for
Non Small Cell Lung Cancer
Criterium, Inc.
Early research (Phase 1)Ended earlyNCT02974725
What this trial is testing

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Who this might be right for
Non-Small Cell Lung CancerMelanoma
Novartis Pharmaceuticals 241
Testing effectiveness (Phase 2)Active Not RecruitingNCT04892017
What this trial is testing

Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
Deciphera Pharmaceuticals, LLC 144
Large-scale testing (Phase 3)Active Not RecruitingNCT05132075
What this trial is testing

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 95
Testing effectiveness (Phase 2)Looking for participantsNCT07148128
What this trial is testing

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Who this might be right for
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal CancerAdvanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer+2 more
Auricula Biosciences Inc.
Large-scale testing (Phase 3)Looking for participantsNCT07190248
What this trial is testing

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 675
Early research (Phase 1)Ended earlyNCT03948763
What this trial is testing

MRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

Who this might be right for
NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms+1 more
Merck Sharp & Dohme LLC 70
Large-scale testing (Phase 3)Not Yet RecruitingNCT07242274
What this trial is testing

Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Jemincare 472
Early research (Phase 1)Ended earlyNCT04965818
What this trial is testing

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Who this might be right for
Advanced or Metastatic Solid Tumors Irrespective of Gene AlterationsNon-Small Cell Lung CancerKRAS Gene Mutation
Taiho Oncology, Inc. 38
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Large-scale testing (Phase 3)Looking for participantsNCT06119581
What this trial is testing

First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
Eli Lilly and Company 1,016
Large-scale testing (Phase 3)Looking for participantsNCT06345729
What this trial is testing

Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 600
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07294261
What this trial is testing

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

Who this might be right for
Local Advanced or Metastatic NSCLC
Sun Yat-sen University 69
110